Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,622Revenue (TTM) $M5.4Net Margin (%)-4,930.2Altman Z-Score6.1
Enterprise Value $M1,321EPS (TTM) $-5.5Operating Margin %-4,920.3Piotroski F-Score4
P/E(ttm)--Beneish M-Score-0.3Pre-tax Margin (%)-4,930.2Higher ROA y-yN
Price/Book5.310-y EBITDA Growth Rate %6.6Quick Ratio4.8Cash flow > EarningsY
Price/Sales2945-y EBITDA Growth Rate %35.4Current Ratio5.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-83.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-111.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M54.8ROIC % (ttm)-969.4Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

SRPT is held by these investors:



SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Mahatme SandeshSenior Vice President, CFO 2016-10-17Sell30,000$50.08-34.88view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-22Sell40,179$60-45.65view
Howton David TSVP, General Counsel 2016-09-22Sell7,000$60-45.65view
Ruff ShamimSVP, Regulatory Affairs & Qual 2016-09-22Sell7,311$60-45.65view
Aphale JayantVP, Technical Operations 2016-09-19Sell35,000$50-34.78view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-19Sell24,352$50-34.78view
Howton David TSVP, General Counsel 2016-09-19Sell9,304$50-34.78view
Kaye Edward M. MDSVP Interim CEO & CMO 2016-09-14Sell24,557$308.7view
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.28100.31view
Barry RichardDirector 2016-03-14Buy75,000$15.66108.24view

Press Releases about SRPT :

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, I Apr 18 2017 
Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developme Apr 17 2017 
Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Apr 05 2017 
Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical O Apr 03 2017 
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 31 2017 
Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to t Mar 30 2017 
Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference Mar 17 2017 
Steven Cohen Sells Alphabet, Apple, Amazon Mar 07 2017 
Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Co Mar 02 2017 
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 

More From Other Websites
Barron's Picks And Pans: Bank Stocks, O'Reilly Automotive, Sarepta And More Apr 23 2017
[$$] Drugmaker Sarepta's Stock Could Double Apr 21 2017
Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : April 19, 2017 Apr 19 2017
Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics,... Apr 18 2017
Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : April... Apr 18 2017
FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG... Apr 18 2017
Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate... Apr 17 2017
Shark Bites: You Don't Want to Play the Gambler Today Apr 13 2017
Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride Apr 12 2017
Today's Research Reports on Biotech Stocks to Watch: Sarepta Therapeutics and Novavax Apr 06 2017
Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Apr 05 2017
Why Sarepta Can Gain 45% Apr 05 2017
Biotech Movers: Sarepta, Bellicum, Novavax Apr 05 2017
Sarepta Gets An Upgrade; Cardiac, Pulmonary Function Could Provide Added Clinical Support For... Apr 05 2017
Sarepta chief hands over CMO role to former Regeneron exec Apr 03 2017
Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical... Apr 03 2017
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 31 2017
Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report? Mar 31 2017
Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to... Mar 30 2017
Market Is Home on the Range Again Mar 22 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)